Laxation response: patient assessment of change in bowel status at the end of trial · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone lower dose showed no clear difference in laxation response: patient assessment of change in bowel statusgat… compared with higher dose (low certainty).
1 finding from 1 review
Symptoms of opioid withdrawal in the medium term · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone lower dose showed no clear difference in symptoms of opioid withdrawal in the medium term compared with higher dose (low certainty).
1 finding from 1 review
Serious adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone lower dose showed no clear difference in adverse events compared with higher dose (low certainty).
1 finding from 1 review
Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Low dose naldemedine may leads to lower laxation response: risk of spontaneous rescue‐free bowel movements… compared with higher doses (low certainty).
1 finding from 1 review
Laxation response: patient assessment of change in bowel status at the end of trial · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Systolic blood pressure · people with CKD
1 finding from 1 review
Diastolic blood pressure · people with CKD
1 finding from 1 review
Albuminuria · people with CKD
1 finding from 1 review
Extracellular fluid volume · people with CKD
1 finding from 1 review
Weight (kg) · people with CKD
1 finding from 1 review
Reduction in antihypertensive dose · people with CKD
It is very uncertain whether lower salt intake changes reduction in antihypertensive dose compared with higher salt intake (very low certainty).
1 finding from 1 review
Symptomatic hypotension · people with CKD
Lower salt intake probably leads to higher symptomatic hypotension compared with higher salt intake (moderate certainty).
1 finding from 1 review
Death (all causes) · primary immunosuppression in kidney transplant recipients
Low showed no clear difference in death (all causes) compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).
1 finding from 1 review
Graft loss including death · primary immunosuppression in kidney transplant recipients
Low showed no clear difference in total graft loss (with death) compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).
1 finding from 1 review
Biopsy‐proven acute rejection · primary immunosuppression in kidney transplant recipients
Low probably leads to higher biopsy‐proven acute rejection compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).
1 finding from 1 review
CMV infection · primary immunosuppression in kidney transplant recipients
Low showed no clear difference in CMV infection compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).
1 finding from 1 review
Malignancy · primary immunosuppression in kidney transplant recipients
Low showed no clear difference in all malignancy compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).
1 finding from 1 review
Number needing to change treatment · primary immunosuppression in kidney transplant recipients
Low showed no clear difference in number needing to change treatment compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (low certainty).
1 finding from 1 review